About
Jason joined Sanofi Ventures in 2014 with a background in early-stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at Translate Bio (fka RaNA Therapeutics), a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space. Jason’s active investments include Abcuro, AdvanCell, Atalanta Therapeutics, Character Bio, Expedition Therapeutics, Glycomine, Matchpoint Therapeutics, Nura Bio, ReCode Therapeutics, Star Therapeutics, and Vrata. Previous investments include Escient Pharmaceuticals (acquired by Incyte), Q32 Bio (NASDAQ: QTTB), Icosavax (acquired by AstraZeneca), Kymera Therapeutics (NASDAQ: KYMR), Ovid Therapeutics (NASDAQ: OVID), Science 37 (NASDAQ: SNCE), and Lysosomal Therapeutics Inc. (acquired by Bial). Jason also serves as the Chair of the Board of Trustees of the Buckingham Browne and Nichols school and the Board of Directors of The Magdalene College Foundation. Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.
Sign up to see Jason P. Hafler's full profile
Access investment thesis, focus areas, bio, and contact details for Jason P. Hafler and 22,000+ other VC professionals.